METRONIDAZOLE INJECTION 500MG/100ML
Each 100 mL of the solution contains 500 mg Metronidazole.
Metronidazole is active against a variety of anaerobic bacteria,
particularly Bacteroides fragilis.
Its mechanism of action is reflected in a selective toxicity to
anaerobic or microaerophilic micro-organisms
and for other, anoxic or hypoxic cells.
In susceptible cells, the nitro group of metronidazole is reduced
by electrontransport proteins with low redox potentials (such as
ferredoxin in clostridia); these proteins play a much more
important role in the metabolism
of such cells than they do in aerobes.
|1.||The treatment of infections in which anaerobic bacteria have been
identified or are suspected as pathogens, particularly Bacteroides
fragilis and other species of bacteroides and including other
species for which metronidazole is bactericidal.|
|2.||For the prevention of post-operative abdominal and pelvic
infections due to anaerobic bacteria.|
Metronidazole should not be used on patients with blood dyscrasias
or with active disease of the central nervous system. Its use
should be avoided during pregnancy. If its use is essential during
pregnancy the short high dose regiments should not be used.
DOSAGE AND DIRECTIONS FOR USE:
Adults and Children over 12 years
100 mL by intravenous infusion eight hourly. The injection should
be infused intravenously at the rate of 5 mL per minute, but may be
administered alone or concurrently but separately, with other
bacteriologically appropriate antibacterial agents in parenteral
dosage forms. Oral medication with 400 mg three times daily should
be substituted as soon as this becomes feasible. Treatment for
seven days should be satisfactory for most patients but, depending
upon clinical and bacteriological assessments, the physician might
decide to prolong treatment, e.g. for the eradication of infection
from sites which cannot be drained or are liable to endogenous
recontamination by anaerobic pathogens from the gut, oropharynx or
Children under 12 years
As for adults, but the single intravenous dose is based on 1,5
mL/kg body mass (7,5 mg metronidazole/kg body mass) and the oral
dose of 7 mg/kg body mass.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Gastro-intestinal discomfort, anorexia, nausea, coated tongue,
dryness of mouth, unpleasant taste, headache and skin rash.
Vertigo, depression, insomnia, drowsiness, urethral discomfort and
darkening of the urine may occur.
There may be a temporary decrease in the total white-cell count.
When given in conjunction with alcohol, metronidazole may provoke a
disulfiram type reaction in some individuals
Protect from light.
Store below 25°C.
KEEP OUT OF REACH OF CHILDREN.